bioRxivNeurosciencePreprint
Donor Aware Reanalysis of Neuronal Nuclei Supports STMN2 Depletion Associated with Nuclear TDP 43 loss in FTD and ALS
Abstract
Background. Nuclear TDP-43 depletion is a central pathological feature of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), but donor-to-donor variation can obscure transcriptomic associations in small postmortem cohorts. We reanalyzed public RNA-seq data from FACS-isolated NeuN-positive frontal-cortex neuronal nuclei to quantify gene-expression changes associated with nuclear TDP-43 loss while explicitly accounting for donor structure. Methods. The supplied GSE126542-derived matrix contained 62,754 genes across 12 libraries from seven donors, including five complete matched pairs. Source labels TDP-43 positive and TDP-43 negative were harmonized as nuclear TDP-43 retained and lost, respectively. After validation against featureCounts-assigned read counts, 44,225 genes with at least 10 total counts were analyzed using PyDESeq2. The primary model was ~ donor + nuclear_status; status-only and diagnosis-adjusted models were sensitivity analyses. The contrast was TDP-43 loss minus retained. Results. The donor-aware model identified 3,442 genes at false discovery rate (FDR) < 0.05: 1,865 lower and 1,577 higher in TDP-43-loss nuclei. STMN2 was consistently depleted (log2 fold change = -1.813, 95% Wald interval -2.229 to -1.396; FDR = 6.22e-15), corresponding to approximately 71.5% lower expression. Normalized STMN2 counts were lower in TDP-43-loss nuclei in all five complete donor pairs. TARDBP expression was also lower (log2 fold change = -0.606; FDR = 4.98e-6). In contrast, UNC13A whole-gene expression was modestly higher in the donor-aware model (log2 fold change = 0.372; FDR = 0.00622) and was not significant in either sensitivity model. Conclusions. Donor-aware analysis supports a robust association between nuclear TDP-43 loss and STMN2 depletion in this neuronal-nuclei cohort, alongside extensive but model-dependent transcriptomic variation. Whole-gene UNC13A expression cannot be used to infer UNC13A cryptic-exon inclusion or functional UNC13A depletion. No splice-junction, percent-spliced-in, isoform, or protein measurements were available; mechanistic claims therefore require junction-level and experimental validation.
- organism: human
- assay: bulk RNA-seq
- research focus: differential expression
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Novel and known transcriptional targets of ALS/FTD protein TDP-43: Meta-analysis and interactive graphical databases
Maize C. Cao, Emma L. Scotter·Disease Models & MechanismsPeer-reviewed·Aug 10, 2022
- TDP-43 nuclear loss in FTD/ALS causes widespread alternative polyadenylation changes
Yi Zeng, Anastasiia Lovchykova, … Aaron D. Gitler·bioRxiv·Jan 22, 2024
- pTDP-43 levels correlate with cell type specific molecular alterations in the prefrontal cortex of C9orf72 ALS/FTD patients
Hsiao‐Lin V. Wang, Jian‐Feng Xiang, … Zachary T. McEachin·Proceedings of the National Academy of SciencesPeer-reviewed·Feb 25, 2025
- Single-cell transcriptomics uncovers chromatin dysfunction in a human TDP-43 proteinopathy model of Amyotrophic Lateral Sclerosis.
Johanna Ganssauge, Harshitha B Chandrashekar, … Akshay Bhinge·bioRxiv·May 13, 2026
- Reduced STMN2 and pathogenic TDP-43, two hallmarks of ALS, synergize to accelerate motor decline in mice
Kelsey L. Krus, Ana Morales Benitez, … Aaron DiAntonio·bioRxiv·Mar 19, 2024
- TDP-43 expression in the cytoplasm leads to early synaptic and mitochondrial abnormalities in an inducible mouse model of ALS/FTD
Florencia Vassallu, Milagros López, … Lionel Muller Igaz·Neurochemistry InternationalPeer-reviewed·May 13, 2026